Variants of vascular endothelial cell growth factor, their...

Details Variants of vascular endothelial cell growth factor, their... Variants of vascular endothelial cell growth factor, their...

2005-06-03

2008-09-23

Spector, Lorraine (Department: 1646)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000

Reexamination Certificate

active

07427596

ABSTRACT:
The present invention involves the preparation of vascular endothelial growth factor (VEGF) variants which provide materials that are selective in respect of binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.

REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3887699 (1975-06-01), Yolles
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4330440 (1982-05-01), Ayers
patent: 4399216 (1983-08-01), Axel et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 5607918 (1997-03-01), Eriksson et al.
patent: 6057428 (2000-05-01), Keyt et al.
patent: 6750044 (2004-06-01), Keyt et al.
patent: 7090834 (2006-08-01), Cunningham et al.
patent: 2006/0063203 (2006-03-01), Cunningham et al.
patent: 2007/0142284 (2007-06-01), Cunningham et al.
patent: 1 176 565 (1984-10-01), None
patent: 0 058 481 (1981-08-01), None
patent: 0 036 776 (1981-09-01), None
patent: 0 075 444 (1983-03-01), None
patent: 0 133 988 (1985-03-01), None
patent: 0 158 277 (1985-10-01), None
patent: 0 160 457 (1985-11-01), None
patent: 0 266 032 (1988-05-01), None
patent: 0 509 477 (1990-09-01), None
patent: WO 87/05330 (1987-09-01), None
patent: WO 90/13649 (1990-11-01), None
Strader et al., Structural basis of beta-adrenergic receptor function, FASEB J. 3:1825-1832, 1989.
Adelman et al., 1983,DNA, 2(3):183-193 “In vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone”.
Aiello et al., 1994,New England J of Medicine, 331(22):1480-1487 “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders”.
Aplin et al., 1981,CRC Crit. Rev. Biochem., 10(4):259-306 “Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids”.
Aviv et al., 1972,Proc. Natl. Acad. Sci. USA, 69(6): 1408-1412 “Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligotymidylic Acid-Cellulose”.
Baenziger, 1984, InThe Plasma Proteins: Structure, Function, and Genetic Control, F.W. Putnam, cds, 2d edition, Adademic Press: New York, vol. IV, Chapter 5, pp. 271-315 “The Oligosaccharides of Plasma Glycoproteins: Synthesis, Structure, and Function”.
Barzu et al., 1985,Biochimica et Biophysica Acta, 845:196-203 “Binding and endocytosis of heparin by human endothelial cells in culture”.
Benton et al., 1977,Science, 196:180-182 “Screening λgt recombinant clones by hybridization to single plaques in situ”.
Bolivar et al., 1977,Gene, 2:95-113 “Construction and Characterization of New Cloning Vehicles. II. A Multipurpose Cloning System”.
Bothwell et al., 1981,Nature, 290:65-67 “Dual expression of λ genes in the MOPC-315 plasmacytoma”.
Breir et al., 1992,Dev., 114:521-532 “Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation”.
Chang, 1978,Nature, 375:615 “Are World Summits Really Necessary”.
Chen et al., 1987,Mol. Cell Biol., 7(8):2745-2752 “High-efficiency transformation of mammalian cells by plasmid DNA”.
Cohen et al., 1972,Proc. Natl. Acad. Sci. USA, 69(8):2110-2114 “Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation ofEscherichia coliby R-Factor DNA”.
Crea et al., 1978,Proc. Natl. Acad. Sci. USA, 75(12):5765-5769 “Chemical Synthesis of Genes for Human Insulin”.
Creighton, T.E., 1983, InProteins: Structure and Molecular Principles, W.H. Freeman & Co., San Francisco pp. 79-86.
Ferrara et al., 1989,Biochem. &Biophys. Res. Comm., 161(2):851-858 “Pituitary Follicular Cells Secrete a Novel Heparin-binding Growth Factor Specific for Vascular Endothelial Cells”.
Ferrara, N., 1995,Laboratory Investigation, 72(6):615-618 “Vascular endothelial growth factor. The trigger for neovascularization in the eye”.
Fiers et al., 1990,Nature, 273:113-120 “Complete Nucleotide Sequences of SV40 DNA”.
Froehler et al., 1986,Nuceleic Acids Research, 14(13):5399-5407 “Synthesis of DNA via Deoxynucleoside H-Phosphonate Intermediates”.
George et al., 1990,Meth. Enzymol., 183:333-351 “Mutation data matrix and its uses”.
GenBank Database, Liang et al., Apr. 1998, Accession No. AAC41274 “vascular endothelial growth factor isoform 165 [Danio rerio]”.
GenBank Database, Eichmann et al., May 1998, Accession No. CAA75799 “vascular endothelial growth factor C [Coturnix coturnix]”.
GenBank Database, Cleaver et al., Jul. 1997, Accession No. AAB63680 “vascular endothelial growth factor 196 [Xenopus laevis]”.
GenBank Database, Junqueira de Azevedo, et al., Oct. 2001, Accession No. AAK52103 “vascular endothelial growth factor precursor [Bothrops jararaca]”.
GenBank Database, Meyer et al., Mar. 1999, Accession No. AAD03735 “vascular endothelial growth factor homolog Vegf-c [Orf virus]”.
Goeddel et al., 1979,Nature, 281:544-548 “Direct Expression inEscherichia coliof a DNA Sequence Coding for Human Growth Hormone”.
Goeddel et al., 1980,Nucleic Acids Research, 8(18):4057-4074 “Synthesis of Human Fibroblast Interferon byE. coli”.
Gorman et al., 1990,DNA Prot. Eng. Tech., 2(1):3-10 “Transient Production of Proteins Using an Andenovirus Transformed Cell Line”.
Graham et al., 1973,Virology, 52:456-467 “A New Technique for the Assay of Infestivity of Human Adenovirus 5 DNA”.
Green et al., 1983,Cell, 32(3):671-694 “Human β-globin pre-mRNA synthesized in vitro is accurately spliced in Xenopus oocyte nuclei”.
Haniu et al., 1993,Biochemistry, 32:2431-2437 “Disulfide bonds in recombinant human platelet-derived growth factor BB dimer: characterization of intermolecular and intramolecular disulfide linkages”.
Hess et al., 1968, InAdvances in Enzyme Regulation, George Weber, New York: Pergamon Press, 7:149-167 “Cooperation of Glycolytic Enzymes”.
Hitzeman et al., 1980,Journal of Biological Chemistry, 255(24):12073-12080 “Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique”.
Holland et al., 1978,Biochemistry, 17(23):4900-4907 “Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase”.
Houck et al., 1992,Journal of Biological Chemistry, 267:26031-26037 “Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms”.
Hsiao et al., 1979,Proc. Natl. Acad. Sci. USA, 76:3829-3833 “High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4Gene”.
Hunter et al., 1962,Nature, 194:495-496 “Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity”.
Huynh et al., 1985,DNA Cloning, A Practical Approach, D.M. Glover 1:49-78 “Constructing and Screening cDNA Libraries in λgt10 and λgt11”.
Itakura et al., 1977,Science, 198:1056-1063 “Expression ofEscherichia Coliof a Chemically Synthesized Gene for the Hormone Somatostatin”.
Jones E., 1977,Genetics, 85(1):23-33 “Proteinas

Affiliated with

Also associated with

Rating

Variants of vascular endothelial cell growth factor, their... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Variants of vascular endothelial cell growth factor, their..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variants of vascular endothelial cell growth factor, their... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3977021